Preclinical study of a novel hydrodynamically levitated centrifugal pump for long-term cardiopulmonary support
An extracorporeal centrifugal blood pump with a hydrodynamically levitated impeller was developed for use in a durable extracorporeal membrane oxygenation (ECMO) system. The present study examined the biocompatibility of the blood pump during long-term use by conducting a series of 30-day chronic animal experiments. The ECMO system was used to produce a percutaneous venoarterial bypass between the venae cavae and carotid artery in adult goats. No anticoagulation or antiplatelet therapy was administered during the experiments. Three out of four animals survived for the scheduled 30-day period, and the blood pumps and membrane oxygenators both exhibited sufficient hydrodynamic performance and good antithrombogenicity, while one animal died of massive bleeding from the outflow cannulation site. The animals’ plasma free hemoglobin had returned to within the normal range by 1 week after the surgical intervention, and their hemodynamic and biochemistry parameters remained within their normal ranges throughout the experiment. The explanted centrifugal blood pumps did not display any trace of thrombus formation. Based on the biocompatibility demonstrated in this study, the examined centrifugal blood pump, which includes a hydrodynamically levitated impeller, is suitable for use in durable ECMO systems.
KeywordsECMO Centrifugal pump Animal experiment Hydrodynamic levitation
This study received financial support from the New Energy and Industrial Technology Development Organization as a Translational Research Project.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351–63.CrossRefPubMedGoogle Scholar
- 8.Eya K, Tatsumi E, Taenaka Y, Takewa Y, Wakisaka Y, Toda K, Nakatani T, Masuzawa T, Baba Y, Miyazaki K, Nishimura T, Ohno T, Ahn JM, Takano H. Development of a membrane oxygenator for long-term respiratory support and its experimental evaluation in prolonged ECMO. ASAIO J. 1996;42:M832–6.CrossRefPubMedGoogle Scholar
- 9.Nishinaka T, Tatsumi E, Taenaka Y, Katagiri N, Ohnishi H, Shioya K, Fukuda T, Oshikawa M, Sato K, Tsukiya T, Homma A, Takewa Y, Takano H, Sato M, Kashiwabara S, Tanaka H, Sakai K, Matsuda T. At least 34 days of animal continuous perfusion by a newly developed extracorporeal membrane oxygenation system without systemic anticoagulants. Artif Organs. 2002;26:548–51.CrossRefPubMedGoogle Scholar